Published in
Taylor and Francis Group, OncoImmunology, 9(7), p. e1472195
DOI: 10.1080/2162402x.2018.1472195
Links
Tools
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
Journal article published in 2018 by
Todd A. Braciak,
Claudia C. Roskopf,
Sarah Wildenhain,
Nadja C. Fenn,
Christian B. Schiller,
Ingo A. Schubert,
Uwe Jacob,
Annemarie Honegger 
,
Christina Krupka,
Marion Subklewe,
Karsten Spiekermann,
Karl-Peter Hopfner,
Georg H. Fey,
Michael Aigner,
Stefan Krause
and other authors.
,
Christina Krupka,
Marion Subklewe,
Karsten Spiekermann,
Karl-Peter Hopfner,
Georg H. Fey,
Michael Aigner,
Stefan Krause
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 